Virbac SA
PAR:VIRP

Watchlist Manager
Virbac SA Logo
Virbac SA
PAR:VIRP
Watchlist
Price: 312 EUR Market Closed
Market Cap: 2.6B EUR

EV/EBITDA
Enterprise Value to EBITDA

10.1
Current
10.2
Median
12.4
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
10.1
=
Enterprise Value
2.7B EUR
/
EBITDA
268.1m EUR
Market Cap EV/EBITDA
FR
Virbac SA
PAR:VIRP
2.6B EUR 10.1
US
Eli Lilly and Co
NYSE:LLY
677.8B USD 32.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
US
Johnson & Johnson
NYSE:JNJ
367.1B USD 12.3
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 12.9
CH
Roche Holding AG
SIX:ROG
206.2B CHF 9.4
CH
Novartis AG
SIX:NOVN
182.2B CHF 10.2
UK
AstraZeneca PLC
LSE:AZN
160.9B GBP 130.6
US
Merck & Co Inc
NYSE:MRK
195.9B USD 8.4
IE
Endo International PLC
LSE:0Y5F
163.5B USD 261.3
FR
Sanofi SA
PAR:SAN
117.1B EUR 5.1
EBITDA Growth EV/EBITDA to Growth
FR
Virbac SA
PAR:VIRP
Average EV/EBITDA: 394.5
10.1
10%
1
US
Eli Lilly and Co
NYSE:LLY
32.9
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.3
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.4
6%
1.6
CH
Novartis AG
SIX:NOVN
10.2
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.6
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.4
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.1
8%
0.6

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
8.9
2-Years Forward
EV/EBITDA
8.2
3-Years Forward
EV/EBITDA
7.6